Table 7.
Selected Trials of Checkpoint Inhibitors in Multiple Myeloma (MM)
| Trial ID (References) | Treatment | Phase | Enrollment (N) | Trial Title |
|---|---|---|---|---|
| PD-1 Inhibitors | ||||
| NCT03848845132 | Pembro + BelMaf | I/II | 41 | A phase I/II single arm open-label study to explore safety and clinical activity of GSK2857916 administered in combination with pembrolizumab in subjects with RRMM (DREAMM 4) |
| NCT04361851311 | Pembro + Dara | II | 33 | Phase II Study of daratumumab-pembrolizumab for MM patients with ≥ three prior lines of therapy |
| NCT03267888 | Pembro + Radiation | I | 24 | Pilot study of pembrolizumab and single-fraction, low-dose, radiation therapy in patients with RRMM |
| NCT03292263 | Niv + ASCT | I | 30 | Autologous stem cell transplantation with nivolumab in patients with MM |
| NCT04205409 | Niv | II | 20 | Nivolumab for relapsed or refractory disease post CAR T-cell treatment in patients with hematologic malignancies, including MM |
| NCT04119336 | Niv + Ixazo + Ctx + Dex | II | 50 | A phase II study of nivolumab in combination with ixazomib, cyclophosphamide, and dexamethasone in RRMM |
| NCT03194867 | Isa + Cem | I/II | 109 | A phase I/II study to evaluate safety, pharmacokinetics and efficacy of isatuximab in combination with cemiplimab in patients with RRMM |
| PD-L1 Inhibitors | ||||
| NCT02431208312 | [Atz ± Len] or [(Atz + Dara) ± (Len or Pom)] | I | 85 | A phase Ib study of the safety and pharmacokinetics of atezolizumab alone or in combination with an immunomodulatory drug and/or daratumumab in patients with MM |
| CD47 Inhibitors | ||||
| NCT03530683305 | TTI-622 | I | 156 | A phase Ia/Ib dose escalation and expansion trial of TTI-622 in patients with advanced relapsed or refractory lymphoma or myeloma |
Abbreviations: Atz, atezolizumab; BelMaf, belantamab mafodotin; Cem, cemiplimab; Ctx, cyclophosphamide; Dara, daratumumab; Dex, dexamethasone; Isa, isatuximab; Ixazo, ixazomib; Len, lenalidomide; Niv, nivolumab; Pembro, pembrolizumab; Pom, pomalidomide.